78 results about "Heart Injury" patented technology

The present invention provides a method of post-conditioning reperfusion of an organ or tissue injured by ischemia. Also provided is a method of treating a myocardial infarction in a subject to prevent injury to the heart following reperfusion of the heart.

The invention provides a kit and a method for in vitro directional differentiation of human-derived iPS stem cells into myocardial cells. By virtue of a nutrient solution provided by the kit disclosed by the invention and in accordance with the method disclosed by the invention, the efficient and directional differentiation of the iPS stem cells into the myocardial cells is promoted. The kit and the method disclosed by the invention are simple and reliable, stable and efficient and high in safety, and the differentiation proportion of the multipotential stem cells into the myocardial cells is significantly increased to be greater than 90%. Meanwhile, the kit and a culture medium disclosed by the invention are applicable to the large-scale production of high-quality myocardial cells, without subsequent screening and purifying steps; and the kit and the culture medium are directly applicable to heart development scientific researches, cell therapy of heart diseases, transplantation for heart injury and application demand of drug screening.

The invention relates to one section of thymosin beta 4 derivatives with high bioactivity which can be used to repair cornea, skin, and heart injury.

The invention relates to novel pharmacological action of traditional Chinese medicine salvianolic acid A and application thereof in the preparation of products for preventing, relieving and/or treating pulmonary arterial hypertension and its complications. The salvianolic acid A has the advantages that the salvianolic acid A has the pharmacological action of relieving pulmonary circulation pressure rise, the pharmacological actions of relieving right heart failure due to pulmonary arterial hypertension, improving right ventricular hypertrophy and right ventricular enlargement, improving heart injury due to pulmonary arterial hypertension, and restoring from heart failure, and the pharmacological actions of lowering endothelin-1 level in pulmonary tissues, relieving pulmonary arterial remodeling and improving pathologic damage of pulmonary tissues; the salvianolic acid A is a monomer compound extracted from Salvia miltiorrhiza, has low toxicity, has a wide source range of material, has promising application and development prospect, is an ideal novel traditional Chinese medicine monomer for treating pulmonary arterial hypertension and its complications, and may be applied to prepare products for preventing, relieving and treating pulmonary arterial hypertension and its complications, such as chronic obstructive pulmonary emphysema, chronic pulmonary heart disease and heart failure.

The invention relates to markers for acute myocardial infarction (AMI), particularly markers that may be used in the rapid and accurate diagnosis of AMI or reinfarction. A method of diagnosing cardiac injury comprising identifying an elevated concentration of cardiac myosin binding protein C (cMyBP-C) or a fragment thereof or myosin regulatory light chain 2 (MLC2) or a fragment thereof in a sample obtained from a subject.

The invention relates to an application of p-hydroxyphenylacetic acid in prevention and/or treatment of cardiovascular diseases. The invention finds for the first time that p-hydroxyphenylacetic acidhas a good treatment effect on vascular and cardiac injuries. For zebra fish interbody vascular (ISV) injury and subintestinal vein (SIV) growth conditions induced by a vascular endothelial cell growth factor receptor inhibitor (PTK787), p-hydroxyphenylacetic acid has a remarkable effect of promoting angiogenesis, and the generation number and the length of blood vessels can be obviously increased. The traditional Chinese medicine composition has a remarkable heart protection effect on heart failure of zebra fish induced by verapamil, arrhythmia induced by terfenadine and p-hydroxyphenylaceticacid, and can obviously reduce cardiac dilatation, relieve venous congestion and promote the heart rate to tend to be normal.

The invention discloses an exposure device and a method for minimally invasive operating room septal defects, and relates to the technical field of medical apparatus and instruments. The invention solves the cardiac injury caused easily in the process of stretching and exposing the ventricular septal defect, The technical scheme comprises a hand-held box, a tube fixedly connected with the hand-held box and a first air bag fixedly connected with the outer wall of the tube, wherein the first air bag is circumferentially arranged along the tube body; The hand-held box is provided with a syringe for storing normal saline, and the pipe is provided with a liquid infusion pipe which is respectively communicated with the syringe and the first air bag at two ends. The injection barrel is movably connected with a sealed piston, and the hand box is movably connected with an operation rod for driving the sealed piston to move, which has the effects of reducing heart injury and simplifying the operation of pulling and exposing the ventricular septal defect.

The invention provides a composition for activating cardiac regeneration. The composition contains an Erk1/2 phosphorylation level positive regulator. The invention further relates to application of Mek1/2 protein, Erk1/2 dephosphorylated inhibitor, hydrogen peroxide or NOX family proteins in preparing a cardiac regeneration activating medicine. Upon experiments, the invention discovers a signal pathway which is capable of activating cardiac regeneration capacity, and by regulating the signal pathway from various links, the cardiac regeneration capacity is activated. By operating a heart injury surface and activating the cardiac regeneration capacity, the composition can be used for effectively treating heart injury and reducing death rate.

The invention provides a pharmacological mechanism of radix astragali seu hedysari pulse-activating decoction capable of preventing radiation-induced heart injury. A preparation method comprises the following steps: adding water into radix astragali seu hedysari for decocting, and then filtering; concentrating filtrate till every 1ml filtrate is equivalent to 1 to 2g of raw medicinal material; precipitating with ethanol by two times, wherein the solution contains 75 percent of ethanol in the first time, the solution contains 85 percent of ethanol in the second time; recovering the ethanol and concentrating till every 1ml of ethanol is equivalent to 10g of the raw medicinal material; adding chrysanthemum indicum flower, fructus crataegi, semen raphanin, radix glycyrrhizae and wolfberry fruit and smashing; adding water for soaking, extracting, concentrating and recovering ethanol; adding honey, isomaltose and wine-related yeast species for performing initial fermentation; finally filtering, precipitating, sterilizing and tanking. The radix astragali seu hedysari pulse-activating decoction has the beneficial effects of effectively improving the cardiac function of an irradiated rat, lowering the serum levels of the troponin and creatine kinase-myocardial band (CK-MB) serving as heart injury symbolic molecules, adjusting signal molecules relevant to fibrosis injury such as extracellular matrix, reconstructed enzyme, inflammatory cytokines/chemotactic factor and TGF-beta, and effectively protecting irradiated heart.

The invention discloses application of bitter gourd exosomes in radiation heart injury protection, the bitter gourd exosomes and rat myocardial cells (H9C2) are co-cultured and subjected to radiation treatment, MTT experiments show that 5-25 [mu] g/ml of the bitter gourd exosomes can promote the cell viability of the radiated H9C2 myocardial cells, and 10 [mu] g/ml of the bitter gourd exosomes are selected as the use concentration of the bitter gourd exosomes. Under the condition that the bitter gourd exosome is 10 [mu] g/ml, Ki-67 fluorescent staining proves that the bitter gourd exosome can promote proliferation of radiated H9C2 myocardial cells. An Annexin V-PE/7-AAD flow apoptosis experiment and an apoptosis protein cleaved-caspase3 immunoblotting test prove that the bitter gourd exosome can be used for reducing the apoptosis of H9C2 myocardial cells after radiation. Immunofluorescence staining and protein immunoblotting of a DNA damage marker gamma-H2A. X show that the bitter gourd exosome can reduce DNA damage of H9C2 myocardial cells after radiation.

The invention discloses an application of an alkaloid compound in preparation of a product for preventing and/or treating heart injury, activity research is performed on the alkaloid compound, and it is verified that the alkaloid compound can inhibit apoptosis induced by myocardial toxicity. According to the present invention, by down-regulating the expression level of p-JNK and/or Cleaved-Caspase-3, the myocardial apoptosis induced by the anthracycline drug DOX is inhibited so as to alleviate the myocardial cytotoxicity effect, achieve the myocardial cytotoxicity prevention and/or treatment effect, and can be used for preparing drugs for preventing and/or treating myocardial injury related diseases.